Hepatitis Medicines

Ledifos(Ledipasvir and Sofosbuvir) are the breakthrough treatments for Hepatitis C infections. Its mechanism of action involves inhibiting the enzyme which is necessary for the virus if it is to multiply. A complete cure may even be possible. Chronic hepatitis C is a serious infection of the liver which occurs following an infection with the hepatitis C virus. Upon reaching the cells of the liver, the virus begins to multiply, which it achieves by means of copying its DNA and RNA. This medicine is known as a nucleotide polymerase inhibitor, and it works directly on the virus itself.

After oral administration, it undergoes a process of intracellular metabolism in which it is converted to its active form. It subsequently starts to work, whereupon it actively targets the enzyme that is used by the virus to produce RNA chains (HCV NS5B RNA-dependent RNA polymerase). This can help to stop viral multiplication. Treatment of genotypes 1, 2, 3 and 4 is possible with this medicine, however it is always used in combination with other medications and never on its own.

Dosage and Administration

Ledifos(Ledipasvir and Sofosbuvir) each tablet contain Ledipasvir 90mg + Sofosbuvir 400mg. The dosage schedule must be individualized by the physician in charge of treatment and will vary according to the viral genotype that is being treated. Adult patients will usually be directed by their physician to take 1 tablet per day and it can be administered alongside a meal or else without food.

Those suffering from GT1 or GT4 (genotype 1 or 4) may be ordered by the physician to take it alongside ribavirin and peginterferon alfa, with treatment lasting for a period of 12 weeks. In contrast to this, GT2 (genotype 2) is usually treated for 12 weeks, and it is taken alongside ribavirin. GT3 (genotype 3) requires 24 weeks of treatment in combination with ribavirin. Patients must only take it according to the instructions provided to them by the physician in charge of treatment.

Precautions

Patients who are undergoing treatment for Hepatitis C with Ledifos(Ledipasvir and Sofosbuvir) will require regular visits to their physician or the hospital so that routine blood tests can be carried out. The frequency at which these tests are required will be determined by your physician.

There is a risk of birth defects or other serious harm to an unborn baby associated with this medicine and it should never be taken by pregnant women. A minimum of 2 effective non-hormonal barrier methods of contraception should be used at all times during treatment and for at least 6 months following the completion of treatment.

It is very important that patients are aware of the fact that there is a risk of infecting others with hepatitis C and taking this medicine will not prevent this. Male patients should also not take this medicine if their partner is pregnant, as harm could be caused to an unborn baby if a child is fathered by a man who is taking this medicine.

MyHep LVIR(Ledipasvir and Sofosbuvir) are the breakthrough treatments for Hepatitis C infections. Its mechanism of action involves inhibiting the enzyme which is necessary for the virus if it is to multiply. A complete cure may even be possible. Chronic hepatitis C is a serious infection of the liver which occurs following an infection with the hepatitis C virus. Upon reaching the cells of the liver, the virus begins to multiply, which it achieves by means of copying its DNA and RNA. This medicine is known as a nucleotide polymerase inhibitor, and it works directly on the virus itself.

After oral administration, it undergoes a process of intracellular metabolism in which it is converted to its active form. It subsequently starts to work, whereupon it actively targets the enzyme that is used by the virus to produce RNA chains (HCV NS5B RNA-dependent RNA polymerase). This can help to stop viral multiplication. Treatment of genotypes 1, 2, 3 and 4 is possible with this medicine, however it is always used in combination with other medications and never on its own.

Dosage and Administration

MyHep LVIR(Ledipasvir and Sofosbuvir) each tablet contain Ledipasvir 90mg + Sofosbuvir 400mg. The dosage schedule must be individualized by the physician in charge of treatment and will vary according to the viral genotype that is being treated. Adult patients will usually be directed by their physician to take 1 tablet per day and it can be administered alongside a meal or else without food.

Those suffering from GT1 or GT4 (genotype 1 or 4) may be ordered by the physician to take it alongside ribavirin and peginterferon alfa, with treatment lasting for a period of 12 weeks. In contrast to this, GT2 (genotype 2) is usually treated for 12 weeks, and it is taken alongside ribavirin. GT3 (genotype 3) requires 24 weeks of treatment in combination with ribavirin. Patients must only take it according to the instructions provided to them by the physician in charge of treatment.

Precautions

Patients who are undergoing treatment for Hepatitis C with MyHep LVIR(Ledipasvir and Sofosbuvir) will require regular visits to their physician or the hospital so that routine blood tests can be carried out. The frequency at which these tests are required will be determined by your physician.

There is a risk of birth defects or other serious harm to an unborn baby associated with this medicine and it should never be taken by pregnant women. A minimum of 2 effective non-hormonal barrier methods of contraception should be used at all times during treatment and for at least 6 months following the completion of treatment.

It is very important that patients are aware of the fact that there is a risk of infecting others with hepatitis C and taking this medicine will not prevent this. Male patients should also not take this medicine if their partner is pregnant, as harm could be caused to an unborn baby if a child is fathered by a man who is taking this medicine.

• Brand name: MyHep LVIR
• Contents : Ledipasvir 90mg + Sofosbuvir 400mg
• Marketed by: Mylan Pharmaceuticals Pvt Ltd.
• Form: Tablets
• Packing: Pack of 28 tablets

Ledviclear(Ledipasvir and Sofosbuvir) are the breakthrough treatments for Hepatitis C infections. Its mechanism of action involves inhibiting the enzyme which is necessary for the virus if it is to multiply. A complete cure may even be possible. Chronic hepatitis C is a serious infection of the liver which occurs following an infection with the hepatitis C virus. Upon reaching the cells of the liver, the virus begins to multiply, which it achieves by means of copying its DNA and RNA. This medicine is known as a nucleotide polymerase inhibitor, and it works directly on the virus itself.

After oral administration, it undergoes a process of intracellular metabolism in which it is converted to its active form. It subsequently starts to work, whereupon it actively targets the enzyme that is used by the virus to produce RNA chains (HCV NS5B RNA-dependent RNA polymerase). This can help to stop viral multiplication. Treatment of genotypes 1, 2, 3 and 4 is possible with this medicine, however it is always used in combination with other medications and never on its own.

Dosage and Administration

Ledviclear(Ledipasvir and Sofosbuvir) each tablet contain Ledipasvir 90mg + Sofosbuvir 400mg. The dosage schedule must be individualized by the physician in charge of treatment and will vary according to the viral genotype that is being treated. Adult patients will usually be directed by their physician to take 1 tablet per day and it can be administered alongside a meal or else without food.

Those suffering from GT1 or GT4 (genotype 1 or 4) may be ordered by the physician to take it alongside ribavirin and peginterferon alfa, with treatment lasting for a period of 12 weeks. In contrast to this, GT2 (genotype 2) is usually treated for 12 weeks, and it is taken alongside ribavirin. GT3 (genotype 3) requires 24 weeks of treatment in combination with ribavirin. Patients must only take it according to the instructions provided to them by the physician in charge of treatment.

Precautions

Patients who are undergoing treatment for Hepatitis C with Ledviclear(Ledipasvir and Sofosbuvir) will require regular visits to their physician or the hospital so that routine blood tests can be carried out. The frequency at which these tests are required will be determined by your physician.

There is a risk of birth defects or other serious harm to an unborn baby associated with this medicine and it should never be taken by pregnant women. A minimum of 2 effective non-hormonal barrier methods of contraception should be used at all times during treatment and for at least 6 months following the completion of treatment.

It is very important that patients are aware of the fact that there is a risk of infecting others with hepatitis C and taking this medicine will not prevent this. Male patients should also not take this medicine if their partner is pregnant, as harm could be caused to an unborn baby if a child is fathered by a man who is taking this medicine.

• Medicine Name: Ledviclear
• Active Ingredients: Ledipasvir 90mg and Sofosbuvir 400mg
• Dosage Form: Tablets in bottle.
• Retail Pack: Pack of 28 Tablets
• Company Name: Abbott India

MyHep Contains Sofosbuvir 400mg which cures long-term hepatitis C virus (HCV) issues in specific people. It should be utilized alone or together with ribavirin. Sofosbuvir is actually some kind of HCV nucleotide analog polymerase substance. It minimizes the level of HCV in the human body through avoiding the spread of the HCV inside the human body.

How does MyHep(sofosbuvir) work?

Sofosbuvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is a nucleotide analogue HCV polymerase inhibitor, meaning it blocks the polymerase enzyme which the virus must use to reproduce. Sofosbuvir should be combined with other medications, which may include pegylated interferon (which stimulates the body's own immune response), ribavirin or other direct-acting antivirals that work differently.

Who can use MyHep(sofosbuvir)?

Sofosbuvir is indicated for use by adults with chronic hepatitis C, meaning infection lasting more than six months. It is approved for people with HCV genotype 1, 2, 3, 4, 5 or 6. Genotype 1 is the most common type in Europe and considered the hardest to treat. Sofosbuvir can be used by people being treated for hepatitis C for the first time (known as 'treatment-naive') and for retreatment of people who were not cured with previous interferon-based therapy (known as 'treatment-experienced')

Precautions to be followed while using MyHep (Sofosbuvir):
        Sofosbuvir can easily intermingle with rifamycins, hydantoins and tipranavir so consult the doctor before intake of the medication to avoid complications.Women planning to get pregnant or pregnant ladies should avoid the usage of Sofosbuvir as it may lead to abortion or it may affect the fetus. Breast feeding should also be avoided as it may pass through to new born babies.

Dosage:
         In most cases, you will take one tablet of MyHep each day for a period of 12 weeks.

Side Effects of Sofosbuvir:
         Sofosbuvir raises side effects such as nausea, lack of sleep, skin itching or rash, fever,skin color changes, headache, cough and mouth sores.

• Brand name: MyHep
• Contents : Sofosbuvir 400mg
• Marketed by: Mylan Pharmaceuticals Pvt Ltd.
• Form: Tablets
• Packing: Pack of 28 tablets

HepCvir Contains Sofosbuvir 400mg which cures long-term hepatitis C virus (HCV) issues in specific people. It should be utilized alone or together with ribavirin. Sofosbuvir is actually some kind of HCV nucleotide analog polymerase substance. It minimizes the level of HCV in the human body through avoiding the spread of the HCV inside the human body.

How does HepCvir(sofosbuvir) work?

Sofosbuvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is a nucleotide analogue HCV polymerase inhibitor, meaning it blocks the polymerase enzyme which the virus must use to reproduce. Sofosbuvir should be combined with other medications, which may include pegylated interferon (which stimulates the body's own immune response), ribavirin or other direct-acting antivirals that work differently.

Who can use HepCvir(sofosbuvir)?

Sofosbuvir is indicated for use by adults with chronic hepatitis C, meaning infection lasting more than six months. It is approved for people with HCV genotype 1, 2, 3, 4, 5 or 6. Genotype 1 is the most common type in Europe and considered the hardest to treat. Sofosbuvir can be used by people being treated for hepatitis C for the first time (known as 'treatment-naive') and for retreatment of people who were not cured with previous interferon-based therapy (known as 'treatment-experienced')

Precautions to be followed while using HepCvir (Sofosbuvir):
        Sofosbuvir can easily intermingle with rifamycins, hydantoins and tipranavir so consult the doctor before intake of the medication to avoid complications.Women planning to get pregnant or pregnant ladies should avoid the usage of Sofosbuvir as it may lead to abortion or it may affect the fetus. Breast feeding should also be avoided as it may pass through to new born babies.

Dosage:
         In most cases, you will take one tablet of HepCvir each day for a period of 12 weeks.

Side Effects of Sofosbuvir:
         Sofosbuvir raises side effects such as nausea, lack of sleep, skin itching or rash, fever,skin color changes, headache, cough and mouth sores.

• Medicine Name: HEPCVIR
• Active Ingredients: Sofosbuvir 400mg
• Dosage Form: Tablets.
• Pack Size: 28 Tablets
• Company Name: CIPLA LTD.

Declahep (Daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV).

Natdac (Daclatasvir Dihydrochloride) is a treatment for chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection. It is prescribed with sofosbuvir, and with or without ribavirin.

Dosage and Administration

The recommended dosage in most people is one 60mg tablet taken each day. The tablet is taken orally and should be swallowed whole with a glass of water. It can be taken with or without food.

Treatment with Natdac (Daclatasvir Dihydrochloride) is usually prescribed for a period of 12 weeks.

Natdac should always be taken concurrently with Sofosbuvir.

Natdac should be taken with Sofosbuvir and Ribavarin in the following cases:

§  Genotype 1 infection with decompensated cirrhosis

§  Genotype 1 infection post-transplant

§  Genotype 3 infections with compensated cirrhosis or decompensated cirrhosis

§  Genotype 3 infection post-transplant

Side effects

The most common side effects associated with Natdac (Daclatasvir Dihydrochloride) and Sofosbuvir treatment are headache, fatigue, nausea and diarrhea.

When Natdac is taken with Sofosbuvir and Ribavirin people also report anemia, rash, insomnia, dizziness and somnolence as side effects.

Precautions

Amiodarone when used with Natdac and Sofosbuvir has caused in serious symptomatic bradycardia in some patients. The risk of bradycardia is increased in patients who are taking beta-blockers or patients with heart problems or liver disease.

• Brand Name: Natdac
• Content: Daclatasvir
• Strengths: 60 mg
• Form: Tablets
• Packing: Pack of 28 Tablets
• Manufactured by: Natco Pharma Ltd.

Daclahep (Daclatasvir Dihydrochloride) is a treatment for chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection. It is prescribed with sofosbuvir, and with or without ribavirin.

Dosage and Administration

The recommended dosage in most people is one 60mg tablet taken each day. The tablet is taken orally and should be swallowed whole with a glass of water. It can be taken with or without food.

Treatment with Daclahep (Daclatasvir Dihydrochloride) is usually prescribed for a period of 12 weeks.

Daclahep should always be taken concurrently with Sofosbuvir.

Daclahep should be taken with Sofosbuvir and Ribavarin in the following cases:

§  Genotype 1 infection with decompensated cirrhosis

§  Genotype 1 infection post-transplant

§  Genotype 3 infections with compensated cirrhosis or decompensated cirrhosis

§  Genotype 3 infection post-transplant

Side effects

The most common side effects associated with Daclahep (Daclatasvir Dihydrochloride) and Sofosbuvir treatment are headache, fatigue, nausea and diarrhea.

When Daclahep is taken with Sofosbuvir and Ribavirin people also report anemia, rash, insomnia, dizziness and somnolence as side effects.

Precautions

Amiodarone when used with Daclahep and Sofosbuvir has caused in serious symptomatic bradycardia in some patients. The risk of bradycardia is increased in patients who are taking beta-blockers or patients with heart problems or liver disease.

• Brand Name: DaclaHEP
• Content: Daclatasvir
• Manufactured by: hetero Healthcare
• Strengths: 60mg
• Form: Tablets
• Packing: Pack of 28 Tablets

• Medicine Name: EnteHep
• Active Ingredients: Entecavir 0.5mg/1mg Tablets
• Dosage Form: Tablets.
• Retail Pack: Pack of 10 Tablets
• Company Name: Zydus Heptiza

• Medicine Name: X vir
• Active Ingredients: Entecavir 0.5mg/1mg Tablets
• Dosage Form: Tablets in bottle.
• Retail Pack: Pack of 30 Tablets
• Company Name: Natco Pharma Ltd.

• Brand Name: DaclaHEP
• Content: Daclatasvir
• Manufactured by: hetero Healthcare
• Strengths: 60mg
• Form: Tablets
• Packing: Pack of 28 Tablets

After oral administration, it undergoes a process of intracellular metabolism in which it is converted to its active form. It subsequently starts to work, whereupon it actively targets the enzyme that is used by the virus to produce RNA chains (HCV NS5B RNA-dependent RNA polymerase). This can help to stop viral multiplication. Treatment of genotypes 1, 2, 3 and 4 is possible with this medicine, however it is always used in combination with other medications and never on its own.

Dosage and Administration

Ledipasvir and Sofosbuvir each tablet contain Ledipasvir 90mg + Sofosbuvir 400mg. The dosage schedule must be individualized by the physician in charge of treatment and will vary according to the viral genotype that is being treated. Adult patients will usually be directed by their physician to take 1 tablet per day and it can be administered alongside a meal or else without food.

Those suffering from GT1 or GT4 (genotype 1 or 4) may be ordered by the physician to take it alongside ribavirin and peginterferon alfa, with treatment lasting for a period of 12 weeks. In contrast to this, GT2 (genotype 2) is usually treated for 12 weeks, and it is taken alongside ribavirin. GT3 (genotype 3) requires 24 weeks of treatment in combination with ribavirin. Patients must only take it according to the instructions provided to them by the physician in charge of treatment.

Precautions

Patients who are undergoing treatment for Hepatitis C with Ledipasvir and Sofosbuvir will require regular visits to their physician or the hospital so that routine blood tests can be carried out. The frequency at which these tests are required will be determined by your physician.

There is a risk of birth defects or other serious harm to an unborn baby associated with this medicine and it should never be taken by pregnant women. A minimum of 2 effective non-hormonal barrier methods of contraception should be used at all times during treatment and for at least 6 months following the completion of treatment.

It is very important that patients are aware of the fact that there is a risk of infecting others with hepatitis C and taking this medicine will not prevent this. Male patients should also not take this medicine if their partner is pregnant, as harm could be caused to an unborn baby if a child is fathered by a man who is taking this medicine.

Sofocure Contains Sofosbuvir 400mg which cures long-term hepatitis C virus (HCV) issues in specific people. It should be utilized alone or together with ribavirin. Sofosbuvir is actually some kind of HCV nucleotide analog polymerase substance. It minimizes the level of HCV in the human body through avoiding the spread of the HCV inside the human body.

How does Sofocure(sofosbuvir) work?

Sofosbuvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is a nucleotide analogue HCV polymerase inhibitor, meaning it blocks the polymerase enzyme which the virus must use to reproduce. Sofosbuvir should be combined with other medications, which may include pegylated interferon (which stimulates the body's own immune response), ribavirin or other direct-acting antivirals that work differently.

Who can use Sofocure(sofosbuvir)?

Sofosbuvir is indicated for use by adults with chronic hepatitis C, meaning infection lasting more than six months. It is approved for people with HCV genotype 1, 2, 3, 4, 5 or 6. Genotype 1 is the most common type in Europe and considered the hardest to treat. Sofosbuvir can be used by people being treated for hepatitis C for the first time (known as 'treatment-naive') and for retreatment of people who were not cured with previous interferon-based therapy (known as 'treatment-experienced')

Precautions to be followed while using Sofocure (Sofosbuvir):
        Sofosbuvir can easily intermingle with rifamycins, hydantoins and tipranavir so consult the doctor before intake of the medication to avoid complications.Women planning to get pregnant or pregnant ladies should avoid the usage of Sofosbuvir as it may lead to abortion or it may affect the fetus. Breast feeding should also be avoided as it may pass through to new born babies.

Dosage:
         In most cases, you will take one tablet of Sofocure each day for a period of 12 weeks.

Side Effects of Sofosbuvir:
         Sofosbuvir raises side effects such as nausea, lack of sleep, skin itching or rash, fever,skin color changes, headache, cough and mouth sores.

Hepcinat-LP (Ledipasvir and Sofosbuvir) are the breakthrough treatments for Hepatitis C infections. Its mechanism of action involves inhibiting the enzyme which is necessary for the virus if it is to multiply. A complete cure may even be possible. Chronic hepatitis C is a serious infection of the liver which occurs following an infection with the hepatitis C virus. Upon reaching the cells of the liver, the virus begins to multiply, which it achieves by means of copying its DNA and RNA. This medicine is known as a nucleotide polymerase inhibitor, and it works directly on the virus itself.

After oral administration, it undergoes a process of intracellular metabolism in which it is converted to its active form. It subsequently starts to work, whereupon it actively targets the enzyme that is used by the virus to produce RNA chains (HCV NS5B RNA-dependent RNA polymerase). This can help to stop viral multiplication. Treatment of genotypes 1, 2, 3 and 4 is possible with this medicine, however it is always used in combination with other medications and never on its own.

Dosage and Administration

Hepcinat-LP (Ledipasvir and Sofosbuvir) each tablet contain Ledipasvir 90mg + Sofosbuvir 400mg. The dosage schedule must be individualized by the physician in charge of treatment and will vary according to the viral genotype that is being treated. Adult patients will usually be directed by their physician to take 1 tablet per day and it can be administered alongside a meal or else without food.

Those suffering from GT1 or GT4 (genotype 1 or 4) may be ordered by the physician to take it alongside ribavirin and peginterferon alfa, with treatment lasting for a period of 12 weeks. In contrast to this, GT2 (genotype 2) is usually treated for 12 weeks, and it is taken alongside ribavirin. GT3 (genotype 3) requires 24 weeks of treatment in combination with ribavirin. Patients must only take it according to the instructions provided to them by the physician in charge of treatment.

Precautions

Patients who are undergoing treatment for Hepatitis C with Hepcinat-LP (Ledipasvir and Sofosbuvir) will require regular visits to their physician or the hospital so that routine blood tests can be carried out. The frequency at which these tests are required will be determined by your physician.

There is a risk of birth defects or other serious harm to an unborn baby associated with this medicine and it should never be taken by pregnant women. A minimum of 2 effective non-hormonal barrier methods of contraception should be used at all times during treatment and for at least 6 months following the completion of treatment.

It is very important that patients are aware of the fact that there is a risk of infecting others with hepatitis C and taking this medicine will not prevent this. Male patients should also not take this medicine if their partner is pregnant, as harm could be caused to an unborn baby if a child is fathered by a man who is taking this medicine.

• Medicine Name: HEPCINAT-LP
• Active Ingredients: Sofosbuvir 400mg + Ledipasvir 90mg
• Dosage Form: Tablets.
• Pack Size: 28 Tablets
• Company Name: NATCO PHARMA LTD.

Hepcinat Contains Sofosbuvir 400mg which cures long-term hepatitis C virus (HCV) issues in specific people. It should be utilized alone or together with ribavirin. Sofosbuvir is actually some kind of HCV nucleotide analog polymerase substance. It minimizes the level of HCV in the human body through avoiding the spread of the HCV inside the human body.

How does Hepcinat(sofosbuvir) work?

Sofosbuvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is a nucleotide analogue HCV polymerase inhibitor, meaning it blocks the polymerase enzyme which the virus must use to reproduce. Sofosbuvir should be combined with other medications, which may include pegylated interferon (which stimulates the body's own immune response), ribavirin or other direct-acting antivirals that work differently.

Who can use Hepcinat(sofosbuvir)?

Sofosbuvir is indicated for use by adults with chronic hepatitis C, meaning infection lasting more than six months. It is approved for people with HCV genotype 1, 2, 3, 4, 5 or 6. Genotype 1 is the most common type in Europe and considered the hardest to treat. Sofosbuvir can be used by people being treated for hepatitis C for the first time (known as 'treatment-naive') and for retreatment of people who were not cured with previous interferon-based therapy (known as 'treatment-experienced')

Precautions to be followed while using Hepcinat (Sofosbuvir):
        Sofosbuvir can easily intermingle with rifamycins, hydantoins and tipranavir so consult the doctor before intake of the medication to avoid complications.Women planning to get pregnant or pregnant ladies should avoid the usage of Sofosbuvir as it may lead to abortion or it may affect the fetus. Breast feeding should also be avoided as it may pass through to new born babies.

Dosage:
         In most cases, you will take one tablet of Hepcinat each day for a period of 12 weeks.

Side Effects of Sofosbuvir:
         Sofosbuvir raises side effects such as nausea, lack of sleep, skin itching or rash, fever,skin color changes, headache, cough and mouth sores.

• Medicine Name: HEPCINAT
• Active Ingredients: Sofosbuvir 400mg
• Dosage Form: Tablets.
• Pack Size: 28 Tablets
• Company Name: NATCO PHARMA LTD.

Mydacla (Daclatasvir Dihydrochloride) is a treatment for chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection. It is prescribed with sofosbuvir, and with or without ribavirin.

Dosage and Administration

The recommended dosage in most people is one 60mg tablet taken each day. The tablet is taken orally and should be swallowed whole with a glass of water. It can be taken with or without food.

Treatment with Mydacla (Daclatasvir Dihydrochloride) is usually prescribed for a period of 12 weeks.

Mydacla should always be taken concurrently with Sofosbuvir.

Mydacla should be taken with Sofosbuvir and Ribavarin in the following cases:

§  Genotype 1 infection with decompensated cirrhosis

§  Genotype 1 infection post-transplant

§  Genotype 3 infections with compensated cirrhosis or decompensated cirrhosis

§  Genotype 3 infection post-transplant

Side effects

The most common side effects associated with Mydacla (Daclatasvir Dihydrochloride) and Sofosbuvir treatment are headache, fatigue, nausea and diarrhea.

When Mydacla is taken with Sofosbuvir and Ribavirin people also report anemia, rash, insomnia, dizziness and somnolence as side effects.

Precautions

Amiodarone when used with Mydacla and Sofosbuvir has caused in serious symptomatic bradycardia in some patients. The risk of bradycardia is increased in patients who are taking beta-blockers or patients with heart problems or liver disease.

• Medicine Name: Mydacla 60
• Active Ingredients: Daclatasvir Dihydrocloride 60mg Tablets
• Dosage Form: Tablets in bottle.
• Retail Pack: Pack of 28 Tablets
• Company Name: Mylan India

Sofovir Contains Sofosbuvir 400mg which cures long-term hepatitis C virus (HCV) issues in specific people. It should be utilized alone or together with ribavirin. Sofosbuvir is actually some kind of HCV nucleotide analog polymerase substance. It minimizes the level of HCV in the human body through avoiding the spread of the HCV inside the human body.

How does Sofovir(sofosbuvir) work?

Sofosbuvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is a nucleotide analogue HCV polymerase inhibitor, meaning it blocks the polymerase enzyme which the virus must use to reproduce. Sofosbuvir should be combined with other medications, which may include pegylated interferon (which stimulates the body's own immune response), ribavirin or other direct-acting antivirals that work differently.

Who can use Sofovir(sofosbuvir)?

Sofosbuvir is indicated for use by adults with chronic hepatitis C, meaning infection lasting more than six months. It is approved for people with HCV genotype 1, 2, 3, 4, 5 or 6. Genotype 1 is the most common type in Europe and considered the hardest to treat. Sofosbuvir can be used by people being treated for hepatitis C for the first time (known as 'treatment-naive') and for retreatment of people who were not cured with previous interferon-based therapy (known as 'treatment-experienced')

Precautions to be followed while using Sofovir (Sofosbuvir):
        Sofosbuvir can easily intermingle with rifamycins, hydantoins and tipranavir so consult the doctor before intake of the medication to avoid complications.Women planning to get pregnant or pregnant ladies should avoid the usage of Sofosbuvir as it may lead to abortion or it may affect the fetus. Breast feeding should also be avoided as it may pass through to new born babies.

Dosage:
         In most cases, you will take one tablet of Sofovir each day for a period of 12 weeks.

Side Effects of Sofosbuvir:
         Sofosbuvir raises side effects such as nausea, lack of sleep, skin itching or rash, fever,skin color changes, headache, cough and mouth sores.

• Brand Name : Sofovir
• Generic Name : Sofosbuvir
• Company : Hetero
• Strength : 400mg
• Packing : Pack of 28 Tablets
• Type : Tablets

Velpanat by Natco pharma is a two-drugs Velpatasvir 100mg Sofosbuvir 400mg combination for the treatment of hepatitis C. It is administered as a single daily pill containing the viral NS5A inhibitor velpatasvir and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase.

Velpanat Medicine Details:

• Brand : Velpanat
• Generic : Velpatasvir and Sofosbuvir
• Strength : 100 Mg + 400 Mg
• Form : Tablets
• Packing : Bottle pack of 28 Tablets
• Manufactured by : Natco Pharma

Resof L(Ledipasvir and Sofosbuvir) are the breakthrough treatments for Hepatitis C infections. Its mechanism of action involves inhibiting the enzyme which is necessary for the virus if it is to multiply. A complete cure may even be possible. Chronic hepatitis C is a serious infection of the liver which occurs following an infection with the hepatitis C virus. Upon reaching the cells of the liver, the virus begins to multiply, which it achieves by means of copying its DNA and RNA. This medicine is known as a nucleotide polymerase inhibitor, and it works directly on the virus itself.

After oral administration, it undergoes a process of intracellular metabolism in which it is converted to its active form. It subsequently starts to work, whereupon it actively targets the enzyme that is used by the virus to produce RNA chains (HCV NS5B RNA-dependent RNA polymerase). This can help to stop viral multiplication. Treatment of genotypes 1, 2, 3 and 4 is possible with this medicine, however it is always used in combination with other medications and never on its own.

Dosage and Administration

Resof L(Ledipasvir and Sofosbuvir) each tablet contain Ledipasvir 90mg + Sofosbuvir 400mg. The dosage schedule must be individualized by the physician in charge of treatment and will vary according to the viral genotype that is being treated. Adult patients will usually be directed by their physician to take 1 tablet per day and it can be administered alongside a meal or else without food.

Those suffering from GT1 or GT4 (genotype 1 or 4) may be ordered by the physician to take it alongside ribavirin and peginterferon alfa, with treatment lasting for a period of 12 weeks. In contrast to this, GT2 (genotype 2) is usually treated for 12 weeks, and it is taken alongside ribavirin. GT3 (genotype 3) requires 24 weeks of treatment in combination with ribavirin. Patients must only take it according to the instructions provided to them by the physician in charge of treatment.

Precautions

Patients who are undergoing treatment for Hepatitis C with Resof L(Ledipasvir and Sofosbuvir) will require regular visits to their physician or the hospital so that routine blood tests can be carried out. The frequency at which these tests are required will be determined by your physician.

There is a risk of birth defects or other serious harm to an unborn baby associated with this medicine and it should never be taken by pregnant women. A minimum of 2 effective non-hormonal barrier methods of contraception should be used at all times during treatment and for at least 6 months following the completion of treatment.

It is very important that patients are aware of the fact that there is a risk of infecting others with hepatitis C and taking this medicine will not prevent this. Male patients should also not take this medicine if their partner is pregnant, as harm could be caused to an unborn baby if a child is fathered by a man who is taking this medicine.

Resof Contains Sofosbuvir 400mg which cures long-term hepatitis C virus (HCV) issues in specific people. It should be utilized alone or together with ribavirin. Sofosbuvir is actually some kind of HCV nucleotide analog polymerase substance. It minimizes the level of HCV in the human body through avoiding the spread of the HCV inside the human body.

How does Resof(sofosbuvir) work?

Sofosbuvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is a nucleotide analogue HCV polymerase inhibitor, meaning it blocks the polymerase enzyme which the virus must use to reproduce. Sofosbuvir should be combined with other medications, which may include pegylated interferon (which stimulates the body's own immune response), ribavirin or other direct-acting antivirals that work differently.

Who can use Resof(sofosbuvir)?

Sofosbuvir is indicated for use by adults with chronic hepatitis C, meaning infection lasting more than six months. It is approved for people with HCV genotype 1, 2, 3, 4, 5 or 6. Genotype 1 is the most common type in Europe and considered the hardest to treat. Sofosbuvir can be used by people being treated for hepatitis C for the first time (known as 'treatment-naive') and for retreatment of people who were not cured with previous interferon-based therapy (known as 'treatment-experienced')

Precautions to be followed while using Resof (Sofosbuvir):
        Sofosbuvir can easily intermingle with rifamycins, hydantoins and tipranavir so consult the doctor before intake of the medication to avoid complications.Women planning to get pregnant or pregnant ladies should avoid the usage of Sofosbuvir as it may lead to abortion or it may affect the fetus. Breast feeding should also be avoided as it may pass through to new born babies.

Dosage:
         In most cases, you will take one tablet of Resof each day for a period of 12 weeks.

Side Effects of Sofosbuvir:
         Sofosbuvir raises side effects such as nausea, lack of sleep, skin itching or rash, fever,skin color changes, headache, cough and mouth sores.

Sofocure L(Ledipasvir and Sofosbuvir) are the breakthrough treatments for Hepatitis C infections. Its mechanism of action involves inhibiting the enzyme which is necessary for the virus if it is to multiply. A complete cure may even be possible. Chronic hepatitis C is a serious infection of the liver which occurs following an infection with the hepatitis C virus. Upon reaching the cells of the liver, the virus begins to multiply, which it achieves by means of copying its DNA and RNA. This medicine is known as a nucleotide polymerase inhibitor, and it works directly on the virus itself.

After oral administration, it undergoes a process of intracellular metabolism in which it is converted to its active form. It subsequently starts to work, whereupon it actively targets the enzyme that is used by the virus to produce RNA chains (HCV NS5B RNA-dependent RNA polymerase). This can help to stop viral multiplication. Treatment of genotypes 1, 2, 3 and 4 is possible with this medicine, however it is always used in combination with other medications and never on its own.

Dosage and Administration

Sofocure L(Ledipasvir and Sofosbuvir) each tablet contain Ledipasvir 90mg + Sofosbuvir 400mg. The dosage schedule must be individualized by the physician in charge of treatment and will vary according to the viral genotype that is being treated. Adult patients will usually be directed by their physician to take 1 tablet per day and it can be administered alongside a meal or else without food.

Those suffering from GT1 or GT4 (genotype 1 or 4) may be ordered by the physician to take it alongside ribavirin and peginterferon alfa, with treatment lasting for a period of 12 weeks. In contrast to this, GT2 (genotype 2) is usually treated for 12 weeks, and it is taken alongside ribavirin. GT3 (genotype 3) requires 24 weeks of treatment in combination with ribavirin. Patients must only take it according to the instructions provided to them by the physician in charge of treatment.

Precautions

Patients who are undergoing treatment for Hepatitis C with Sofocure L(Ledipasvir and Sofosbuvir) will require regular visits to their physician or the hospital so that routine blood tests can be carried out. The frequency at which these tests are required will be determined by your physician.

There is a risk of birth defects or other serious harm to an unborn baby associated with this medicine and it should never be taken by pregnant women. A minimum of 2 effective non-hormonal barrier methods of contraception should be used at all times during treatment and for at least 6 months following the completion of treatment.

It is very important that patients are aware of the fact that there is a risk of infecting others with hepatitis C and taking this medicine will not prevent this. Male patients should also not take this medicine if their partner is pregnant, as harm could be caused to an unborn baby if a child is fathered by a man who is taking this medicine.

Virpas (Ledipasvir and Sofosbuvir) are the breakthrough treatments for Hepatitis C infections. Its mechanism of action involves inhibiting the enzyme which is necessary for the virus if it is to multiply. A complete cure may even be possible. Chronic hepatitis C is a serious infection of the liver which occurs following an infection with the hepatitis C virus. Upon reaching the cells of the liver, the virus begins to multiply, which it achieves by means of copying its DNA and RNA. This medicine is known as a nucleotide polymerase inhibitor, and it works directly on the virus itself.

After oral administration, it undergoes a process of intracellular metabolism in which it is converted to its active form. It subsequently starts to work, whereupon it actively targets the enzyme that is used by the virus to produce RNA chains (HCV NS5B RNA-dependent RNA polymerase). This can help to stop viral multiplication. Treatment of genotypes 1, 2, 3 and 4 is possible with this medicine, however it is always used in combination with other medications and never on its own.

Dosage and Administration

Virpas(Ledipasvir and Sofosbuvir) each tablet contain Ledipasvir 90mg + Sofosbuvir 400mg. The dosage schedule must be individualized by the physician in charge of treatment and will vary according to the viral genotype that is being treated. Adult patients will usually be directed by their physician to take 1 tablet per day and it can be administered alongside a meal or else without food.

Those suffering from GT1 or GT4 (genotype 1 or 4) may be ordered by the physician to take it alongside ribavirin and peginterferon alfa, with treatment lasting for a period of 12 weeks. In contrast to this, GT2 (genotype 2) is usually treated for 12 weeks, and it is taken alongside ribavirin. GT3 (genotype 3) requires 24 weeks of treatment in combination with ribavirin. Patients must only take it according to the instructions provided to them by the physician in charge of treatment.

Precautions

Patients who are undergoing treatment for Hepatitis C with Virpas(Ledipasvir and Sofosbuvir) will require regular visits to their physician or the hospital so that routine blood tests can be carried out. The frequency at which these tests are required will be determined by your physician.

There is a risk of birth defects or other serious harm to an unborn baby associated with this medicine and it should never be taken by pregnant women. A minimum of 2 effective non-hormonal barrier methods of contraception should be used at all times during treatment and for at least 6 months following the completion of treatment.

It is very important that patients are aware of the fact that there is a risk of infecting others with hepatitis C and taking this medicine will not prevent this. Male patients should also not take this medicine if their partner is pregnant, as harm could be caused to an unborn baby if a child is fathered by a man who is taking this medicine.

Virso Contains Sofosbuvir 400mg which cures long-term hepatitis C virus (HCV) issues in specific people. It should be utilized alone or together with ribavirin. Sofosbuvir is actually some kind of HCV nucleotide analog polymerase substance. It minimizes the level of HCV in the human body through avoiding the spread of the HCV inside the human body.

How does Virso(sofosbuvir) work?

Sofosbuvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is a nucleotide analogue HCV polymerase inhibitor, meaning it blocks the polymerase enzyme which the virus must use to reproduce. Sofosbuvir should be combined with other medications, which may include pegylated interferon (which stimulates the body's own immune response), ribavirin or other direct-acting antivirals that work differently.

Who can use Virso(sofosbuvir)?

Sofosbuvir is indicated for use by adults with chronic hepatitis C, meaning infection lasting more than six months. It is approved for people with HCV genotype 1, 2, 3, 4, 5 or 6. Genotype 1 is the most common type in Europe and considered the hardest to treat. Sofosbuvir can be used by people being treated for hepatitis C for the first time (known as 'treatment-naive') and for retreatment of people who were not cured with previous interferon-based therapy (known as 'treatment-experienced')

Precautions to be followed while using Virso (Sofosbuvir):
        Sofosbuvir can easily intermingle with rifamycins, hydantoins and tipranavir so consult the doctor before intake of the medication to avoid complications.Women planning to get pregnant or pregnant ladies should avoid the usage of Sofosbuvir as it may lead to abortion or it may affect the fetus. Breast feeding should also be avoided as it may pass through to new born babies.

Dosage:
         In most cases, you will take one tablet of Virso each day for a period of 12 weeks.

Side Effects of Sofosbuvir:
         Sofosbuvir raises side effects such as nausea, lack of sleep, skin itching or rash, fever,skin color changes, headache, cough and mouth sores.

Dosage and Administration

Sofosvel Each tablet contains 400mg of Sofosbuir and 100mg of Velpatasvir.

In most cases, you will take one tablet of Sofosvel each day for a period of 12 weeks. This dosage may need to be adjusted in patients with renal impairment or renal disease.

Sofosvel is taken alone in cases without cirrhosis or with compensated cirrhosis (Child-Pugh A). Sofosvel is used in combination with ribavirin in cases with decompensated cirrhosis (Child-Pugh B and C).

Side effects

The most common side effects of Sofosvel are headache and tiredness. If taken in combination with ribavirin other common side effects are anemia, nausea, insomnia, and diarrhea.

When Sofosvel is used in combination with medicines containing amiodarone it can lead to serious side effects including slowing of the heart rate. This can result in death or need of a pacemaker. If you are taking these medicines in combination, tell your doctor immediately if you notice fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, extreme tiredness, shortness of breath, chest pains, confusion, or memory problems.

Precautions

Prior to taking Sofosvel, make sure you tell your doctor of any medical conditions you have (especially any other liver problems or kidney problems). Tell your doctor if you are pregnant or trying to become pregnant, or if you are breastfeeding or planning to breastfeed.

Dosage and Administration

Sofosvel Each tablet contains 400mg of Sofosbuir and 100mg of Velpatasvir.

In most cases, you will take one tablet of Sofosvel each day for a period of 12 weeks. This dosage may need to be adjusted in patients with renal impairment or renal disease.

Sofosvel is taken alone in cases without cirrhosis or with compensated cirrhosis (Child-Pugh A). Sofosvel is used in combination with ribavirin in cases with decompensated cirrhosis (Child-Pugh B and C).

Side effects

The most common side effects of Sofosvel are headache and tiredness. If taken in combination with ribavirin other common side effects are anemia, nausea, insomnia, and diarrhea.

When Sofosvel is used in combination with medicines containing amiodarone it can lead to serious side effects including slowing of the heart rate. This can result in death or need of a pacemaker. If you are taking these medicines in combination, tell your doctor immediately if you notice fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, extreme tiredness, shortness of breath, chest pains, confusion, or memory problems.

Precautions

Prior to taking Sofosvel, make sure you tell your doctor of any medical conditions you have (especially any other liver problems or kidney problems). Tell your doctor if you are pregnant or trying to become pregnant, or if you are breastfeeding or planning to breastfeed.

Velpanat is a pan-genotopic treatment for Chronic Hepatitis C (HCV), meaning it can be used to treat chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection. It is a fixed-dose combination of sofosbuvir (a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor) and Velpatasvir (an HCV NS5A inhibitor).

Velpanat Each tablet contains 400mg of Sofosbuir and 100mg of Velpatasvir.

In most cases, you will take one tablet of Velpanat each day for a period of 12 weeks. This dosage may need to be adjusted in patients with renal impairment or renal disease.

Velpanat is taken alone in cases without cirrhosis or with compensated cirrhosis (Child-Pugh A). Velpanat is used in combination with ribavirin in cases with decompensated cirrhosis (Child-Pugh B and C).

The most common side effects of Velpanat are headache and tiredness. If taken in combination with ribavirin other common side effects are anemia, nausea, insomnia, and diarrhea.

When Velpanat is used in combination with medicines containing amiodarone it can lead to serious side effects including slowing of the heart rate. This can result in death or need of a pacemaker. If you are taking these medicines in combination, tell your doctor immediately if you notice fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, extreme tiredness, shortness of breath, chest pains, confusion, or memory problems.

Prior to taking Velpanat, make sure you tell your doctor of any medical conditions you have (especially any other liver problems or kidney problems). Tell your doctor if you are pregnant or trying to become pregnant, or if you are breastfeeding or planning to breastfeed.

• Brand name: Velpanat
• Contents : Velpatasvir 100mg + Sofosbuvir 400mg
• Marketed by: Natco Pharma,INDIA
• Form: Tablets
• Packing: Pack of 28 tablets

• Brand name: Velpanat/Velasof
• Contents : Velpatasvir 100mg + Sofosbuvir 400mg
• Marketed by: Natco Pharma/Hetero Pharma,INDIA
• Form: Tablets
• Packing: Bottle Pack of 28 tablets

• Brand name: Velasof
• Contents : Velpatasvir 100mg + Sofosbuvir 400mg
• Marketed by: Hetero Healthcare,INDIA
• Form: Tablets
• Packing: Bottle pack of 28 tablets

Hepatitis C virus (HCV) causes both acute and chronic infection. Acute HCV infection is usually asymptomatic and is only very rarely (if ever) associated with life-threatening disease. About 15–45% of infected persons spontaneously clear the virus within 6 months of infection without any treatment.

The remaining 55–85% of persons will develop chronic HCV infection. Of those with chronic HCV infection, the risk of cirrhosis of the liver is between 15–30% within 20 years.

We have Hepatitis C treatment medicines like Sofosbuvir, Ledipasvir, Ribavirin, Velpatasvir and its combination available with us.

Velasof is a pan-genotopic treatment for Chronic Hepatitis C (HCV), meaning it can be used to treat chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection. It is a fixed-dose combination of sofosbuvir (a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor) and Velpatasvir (an HCV NS5A inhibitor).

Dosage and Administration

Velasof Each tablet contains 400mg of Sofosbuir and 100mg of Velpatasvir.

In most cases, you will take one tablet of Velasof each day for a period of 12 weeks. This dosage may need to be adjusted in patients with renal impairment or renal disease.

Velasof is taken alone in cases without cirrhosis or with compensated cirrhosis (Child-Pugh A). Velasof is used in combination with ribavirin in cases with decompensated cirrhosis (Child-Pugh B and C).

Side effects

The most common side effects of Velasof are headache and tiredness. If taken in combination with ribavirin other common side effects are anemia, nausea, insomnia, and diarrhea.

When Velasof is used in combination with medicines containing amiodarone it can lead to serious side effects including slowing of the heart rate. This can result in death or need of a pacemaker. If you are taking these medicines in combination, tell your doctor immediately if you notice fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, extreme tiredness, shortness of breath, chest pains, confusion, or memory problems.

Precautions

Prior to taking Velasof, make sure you tell your doctor of any medical conditions you have (especially any other liver problems or kidney problems). Tell your doctor if you are pregnant or trying to become pregnant, or if you are breastfeeding or planning to breastfeed.

• Brand name: Velasof
• Contents : Velpatasvir 100mg + Sofosbuvir 400mg
• Marketed by: Hetero Healthcare,INDIA
• Form: Tablets
• Packing: Pack of 28 tablets